A Stimulator of the Salivary Excretion Based on Physical Vibration of the Parotid Glands

Francisco Gómez-García,1 José-Ángel Diaz-Madrid,2 Pía López-Jornet,1 Juan L.G. Guirao3,4,5 and Yolanda Guerrero-Sánchez6

Departamento de Dermatología, Estomatología, Radiología y Medicina Física, Facultad de Medicina y Odontología, Universidad de Murcia, Instituto Murciano de Investigación Biosanitaria (IMIB), Grupo de Investigación Odontología, Spain

Departamento de Ingeniería y Técnicas Aplicadas, Centro Universitario de la Defensa en San Javier, Universidad Politécnica de Cartagena, Spain

Department of Applied Mathematics and Statistics, Technical University of Cartagena Hospital de Marina, 30203 Cartagena, Spain

Department of Mathematics, Faculty of Science, King Abdulaziz University, P.O. Box 80203, Jeddah 21589, Saudi Arabia

Lab Theory Cosmology, International Center of Gravity and Cosmos, TUSUR, 634050 Tomsk, Russia

Department of Anatomy and Psychobiology, University of Murcia, Murcia, Spain

Correspondence should be addressed to Yolanda Guerrero-Sánchez; yolanda.guerreros@um.es

Received 12 October 2021; Accepted 31 January 2022; Published 21 February 2022

Academic Editor: Osamah Ibrahim Khalaf

Copyright © 2022 Francisco Gómez-García et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Oral dryness causes significant health problems both functional (difficulty speaking, chewing and swallowing) and structural in teeth (increased number of infections) and oral mucosa. The main objective of this study is to show an alternative treatment to help stimulate the salivary secretion thus improving the quality of life of the patient. In this study, a salivary stimulation equipment using vibrotactile stimuli is shown. The system has been placed bilaterally in the parotid glands and assessed the efficacy of the salivary secretion by sialometry before and after the stimulation. The new proposal is capable of stimulating salivary secretion, in a significant way after 7 minutes of use, at least in the cases analyzed, and fulfills low-cost, easy-to-use, and safe technical restrictions. In this setting, this paper suggests the performance of a deep clinical trial to measure the exact efficacy of the prototype and the times and frequencies needed to state the optimal treatment depending in each case.

1. Introduction

Xerostomia or subjective sensation of oral dryness is a common manifestation of a series of pathologies, significantly altering the quality of life of patients. The flow of nonstimulated saliva in humans varies between 0.25 and 0.90 ml/min with a mean of approximately 0.4 ml/min. It is the result of the secretion of different glands in different proportions: 20% from PG (parotid glands), 65% from SMG (submandibular glands), 7% to 8% from SLG (sublingual glands), and less than 10% from numerous minor glands. However, given different stimuli (visual, olfactory or gustatory) or parasympathetic activity, saliva flow increases, and in this case, more than 50% of the total secretion is due to PG [1].

The prevalence of xerostomia is high among the general population, affecting 14-46% of adults [2]. The etiology is multifactorial, including chronic diseases (diabetes, Sjögren’s syndrome, rheumatoid arthritis, etc.), disorders of the parotid glands, oral malignant neoplasias, head and neck treatment, and surgery or radiation [3]. Another cause is drugs; medication-induced xerostomia has probably been underestimated, since age in combination with drug use is an important trigger for xerostomia [4]. Therefore, the number of patients suffering from xerostomia and needing symptomatic relief is likely to increase with the aging population [5, 6]. The clinical manifestations that accompany xerostomia are as follows: difficulty speaking, odynophagia; dysphagia, dysgeusia, and halitosis. There is an increase in the
number of caries and greater predisposition to oral superinfections [7, 8].

Treatment for hyposalivation consists of a combination of general measures for good oral hygiene with salivary substitutes. It is recommended to increase the intake of water, lubrication of the mucosa and lips, and avoiding toxic habits, tobacco, alcohol, and the intake of irritating foods [9].

Among the general measures that must be considered is the control of systemic diseases, among the most important of which are Sjögren’s syndrome and the side effects produced by radiotherapy and drugs used in the treatment of head and neck cancer. It is important to consider the psychological factors that are increasingly common in the onset of xerostomia, especially chronic anxiety and excessive stress [10, 11].

At present, there are products in the form of rinses, chewing gums, gels, or sprays, where lubricating agents such as mucin, carboxymethyl cellulose, hydroxyethyl cellulose, xanthan, linseed oil, or propylene glycol are incorporated, among many others [12, 13].

The presentations or formulations that are usually still used in clinical treatments have important limitations. These need constant and repeated use throughout the day because their effects disappear when swallowing, during sleep, and without the natural protection exercised by the saliva in oral structures. All these circumstances, generally, result in a low acceptance of the patient to these products. The same happens mainly with systemic stimulation (pilocarpine, cevimeline), in addition to the many important side effects. So, pilocarpine cause adverse effects in the 30% of patients: mainly sweating, blurred vision, facial redness, increased urinary frequency, diarrhea, bronchospasm, hypotension, and bradycardia. Because of these, patients suffer a high dropout rate [14].

In recent years, nonpharmacological treatments based on electrostimulation have been developed for the treatment of xerostomia by means of different devices such as Saliwell GenNarino® and Saliwell Crown intraoral [15]. These devices increase salivary secretion and cause symptom improvement of dry mouth.

Previous odontological researches show that when the parotid gland is vibrated at a certain frequency, the vibration of the gland causes a stimulation of the salivation [16]. This study presents a new prototype for salivary stimulation. The new prototype is capable of stimulating salivary secretion and fulfills low-cost, easy-to-use, and safe technical restrictions.

2. Materials, Prototyping, and Testing

2.1. General Proposal of Vibrotactile Stimulation Apparatus

Previous research [16] has shown that when the parotid gland is vibrated close to an angular speed of 600 vibrations per minute (vpm), the salivary secretion is stimulated. Therefore, the clamping system must press the cheeks adequately so that when the system vibrates, the cheeks also vibrate with the same frequency without causing any damage to the skin (Figure 1).

The presentations or formulations that are usually still used in clinical treatments have important limitations. These need constant and repeated use throughout the day because their effects disappear when swallowing, during sleep, and without the natural protection exercised by the saliva in oral structures. All these circumstances, generally, result in a low acceptance of the patient to these products. The same happens mainly with systemic stimulation (pilocarpine, cevimeline), in addition to the many important side effects. So, pilocarpine cause adverse effects in the 30% of patients: mainly sweating, blurred vision, facial redness, increased urinary frequency, diarrhea, bronchospasm, hypotension, and bradycardia. Because of these, patients suffer a high dropout rate [14].

In recent years, nonpharmacological treatments based on electrostimulation have been developed for the treatment of xerostomia by means of different devices such as Saliwell GenNarino® and Saliwell Crown intraoral [15]. These devices increase salivary secretion and cause symptom improvement of dry mouth.

Previous odontological researches show that when the parotid gland is vibrated at a certain frequency, the vibration of the gland causes a stimulation of the salivation [16]. This study presents a new prototype for salivary stimulation. The new prototype is capable of stimulating salivary secretion and fulfills low-cost, easy-to-use, and safe technical restrictions.

2.2. Principles of Operation and Description of the Prototype

2.2.1. Principles of Operation of the Prototype. Figure 2 shows the drawings of the prototype that has been manufactured, a simplified block diagram of the electronic system to generate the vibrations is shown in Figures 3 and 4 detailing the right vibrator module together with the right closing housing, the right cavity, and part of the main support. This prototype achieves an increased salivary secretion through the application of high frequency mechanical microvibrations in the parotid glands.

The central idea of the device resides in transmitting the vibration generated by two vibrating modules to the two parotid glands through the superficial contact established between each vibrating module and the respective parotid gland, achieving the stimulation of both parotid glands simultaneously.

Therefore, the system has left and a right vibrator modules that are independent and symmetrical with respect to a vertical symmetry axis. The design symmetry established between the two vibrator modules, left and right, subsequently allows their coupling on the left and right parotid gland, respectively.
This system provides an answer to a chronic health problem with the aim of achieving a better quality of life, based on the mechanical vibration of the parotid glands. With this stimulation device, side effects are few or very mild, perhaps occasionally a slight skin contact erythema, but at present, there are no other known specific solutions that allow the parotid glands to vibrate simultaneously at high frequency in a way that is useful, safe, and comfortable.

The elements of the device are made of standard low-density polymeric materials such as polylactic acid, which favors a low manufacturing cost as well as giving it the quality of having a light weight about 100 g, which added to its small volume making it an easily portable device. It is a non-invasive device because its placement is external, without compressing the neck, as well as being ergonomic, adjustable, and easy to use through the main and secondary supports. During its application, the patient do not have to be seated, being able to move freely. With respect to the electrical specifications, micromotors operate with a supply voltage from 0.5 V to 1.5 V while the current consumption is between 0 mA and 31 mA. The rechargeable battery allows operating autonomously for at least 10 hours.

2.2.2. Physical Description of the Prototype. The system has two vibrator modules, right (1) and left (2), which have a shape corresponding to the physiognomy of the parotid gland with the outer surface of both modules (3) being flat and smooth. The inner side of the vibrator modules (1, 2) is designed to couple with the left (10) and right (11) locking housings, which in turn are the extreme part of the main support (7) of which they are part.

Both the right vibrator module (1) and the left vibrator module (2) have a central hollow piece (4) where the vibrating micromotors (6) are coupled and three threaded holes (5) to allow the through bolts coming from the closing housings to be screwed (10, 11) and that makes the assembly of these with the vibrator modules possible (1, 2) thus achieving the closure and sealing of the set of both elements.

The generation of the high-frequency microvibrations in each vibrator module (1, 2) is achieved by means of two micromotors (6) that are coupled in the central hollow piece (4) of the left (10) and right (11) closing housings, respectively. The micromotors (6) are capable of vibrating at high frequencies when a certain electrical voltage is applied to them. The frequency of the motor vibrations depends on the applied voltage and the mechanical-electrical characteristics of the motor. In the present example, the input range of the applied voltage is 0 to 5 V and the range of the vibration frequency is 0 to 300 Hz.

The two vibrator modules (1, 2) are connected to the main support (7) by means of the locking housings (10, 11). The main support (7) also has two cavities on the left (8) and right (9) to house the electrical connections of the micromotors (6) which are connected to the power cable (19) coming from the electronic control box (16). The cables from the electronic control box enter the left (8) and right (9) cavities of the bracket through two holes placed at the bottom of the cavities (8, 9), which are closed with an inner...
cover (15) that is screwed over each cavity (8, 9). The electronic control box (16) has a display (17) and an alphanumeric keypad (18).

The device has a secondary support (12) in the form of a headband which opens from its ends and which is mechanically connected to the left (10) and right (11) closing housing. At the ends of the secondary support (12), there is a vertical slot (14) through which a central clamping screw (13) can be mechanically moved, allowing the rotation and vertical translation movements of the secondary support (12) with respect to said central clamping screw (13), for an adjustment according to the patient’s anatomy.

Another of its functions is to favor the coupling of the secondary support (12) with the main support (7) and with the vibrator modules (1, 2). This secondary device (12) is removable from the device assembly by completely unscrewing the central tightening screw (13). Figure 5 shows a photo of the salivary stimulator that has been manufactured.

2.3. Design Qualification Tests. This study shows the first phase for the validation of the salivary stimulator. The sample was made up of 15 healthy patients from the University of Murcia (UMU) dental clinic, and each patient was interviewed and informed of the purpose of the study. The inclusion criteria were patients over 18 years old without pharmacological treatment, and all patients signed the consent form. Those patients who suffer a partial or total resection of salivary glands, carry a pacemaker, and were or are undergoing chemotherapy or radiotherapy treatment were excluded. Moreover, other patients with problems in motor skills, to follow the operator’s indications, as well as patients with uncontrolled systemic diseases and pregnant women were also rejected. The present study was conducted in accordance with the ethical principles of the Declaration of Helsinki and Good Clinical Practice and was approved by the Ethics Committee of the University of Murcia (Murcia, Spain), and our trial has been registered with ID no. NCT05129111; this study has been registered retrospectively.

2.3.1. Measurement of Salivary Secretion at Rest and Stimulated Conditions. All patients underwent an initial salivary flow measurement test where the participants were asked not to eat, chew gum, or drink alcoholic beverages at least 1 hour beforehand. The tests were performed between 9:00 am and 11:00 am, in a relaxed and quiet environment with a temperature of about 20°C.

For sialometry, a standardized and previously validated test was used. This test consists of measuring the amount of saliva produced during a period of 5 min when a millimeter strip of paper with a dimension of 1 cm wide and 17 cm is applied. This sialometry test will be used during the qualification test to measure the efficiency of the salivary stimulator under several configurations. Before starting with the validation test, the total saliva excretion has to be measured at rest with the standardized sialometry test. Once finished, the patients had to wait for 3 min before applying the treatment.
For the first application of the stimulator, the head-
phones of the salivary stimulator were placed in the preauri-
cular region and the salivary stimulator was configured with
the following parameters: a vibration of 600 vpm, a fre-
quency of 300 Hz, and a power of 100% in both modules,
right and left, for a period of 5 min. The second sialome-
try lasted for 7 minutes.

On the other hand, a qualitative test was done; the test
consisted of a survey given to the participants to evaluate
the performance of the salivary stimulator according to
personal perception, with regard to the following param-
eters: the design of the stimulator, the fit/comfort of the
stimulator, the level of vibration, and the degree of dis-
comfort/irritation experienced. The parameters were cate-
gorized as follows: 0—very poor, 1-2—poor, 3-4—fair, 5-
6—average, 7-8—good, 9—very good, and 10—excellent.
In addition, at the end of the survey, the participant
described any observations or adverse effects produced
by the use of the salivary stimulator. These effects could
be classified as slight preauricular redness, annoying vibra-
tion, adjustment problems, and vibration dizziness. The
measurement of the salivary secretion was done via
López-Jornet et al.’s test [17].

3. Results

In the pilot clinical trial carried out on 15 healthy patients
to verify the efficacy of the prototype, we observed that the use
of the stimulator increased the sialometry values with
respect to the baseline levels, as shown in Figure 6, obtained
with the Matlab boxplot.

The mean value of salivary flow obtained for the basal
test was 6.24 mm/min. When the salivary stimulator was
applied for 3 min, the mean salivary flow reached a value
of 6.9 mm/min, and finally, when the treatment was applied
up to 7 min, this value increased to 8.27 mm/min. This
means that the application of the 3-minute test resulted in
a 10.57% increase in salivary flow, whereas if the test was
applied up to 7 minutes, the average salivary flow increased
by 32.58%.

Therefore, the saliva flow levels obtained at 7 minutes are
substantially higher than baseline and acceptably higher
than the flow obtained at 5 minutes. So, it can be expan-
oded that the device seems to be more effective the longer
the application time. Regarding the perception of the design,
the majority (66.66%) consider it very good compared to
6.67% who consider it susceptible to improvement (see
Figure 7).

Regarding the feeling of comfort, the highest percentage
(33.33%) is perceived as very good and the rest is distributed
between intervals that go from a good feeling to not very
comfortable. The percentage that considers it to be
improved is high, so we could extrapolate the fact of imple-
menting improvements in the device that were aimed at
turning it into a more comfortable and functional design.
The levels of vibration (perception) are acceptable for a large
part of the sample, and the percentage that considers it an
annoying variable is small (see Figure 7).

Regarding the level of irritation that occurs after the
application of the device, most of the sample perceives an
increase with respect to the initial feeling of comfort, that
is, the longer the patients wear the device; the characteristics
that were previously evaluated in a positive way decrease.
This confirms that it is necessary to implement a series of
improvements that make the device a comfortable and effec-
tive tool at the same time (see Figure 7).

In the test carried out at the end of the study, the partic-
ipants reported a good or very good general feeling after
using the device (Figure 8).

The adverse effects collected included slight preauricular
redness (46.6%), annoying vibration (26.6%), adjustment
problems (20%), and vibration dizziness (8.6%). 26.6%
did not report any adverse effect.

3.1. Statistical Analysis. The Shapiro-Wilk normality test
was used to test whether the samples are normally distrib-
uted. The results showed that all three samples have a
nonnormal distribution. Consequently, we use nonpara-
metric inference to study the influence of the stimulator.

![Figure 5: Photo of the salivary stimulator.](image)

![Figure 6: Salivary flow rate measurement for a basal test without a
stimulator, a 5-minute test, and a 7-minute test with a stimulator.](image)
on salivary flow. Once the test data were obtained from the healthy patients, the Friedman test was applied because there is a group of 15 items where 3 tests (basal test, 5-minute test, and 7-minute test) are applied to each of the items. The null hypothesis being tested is that the responses associated with each of the tests have the same probability distribution with the same median versus the alternative hypothesis that at least one response distribution differs from the others. The results obtained are shown in Tables 1 and 2.

The test statistic is equal to 8.982, so the null hypothesis cannot be rejected for significance levels greater than 0.011. Therefore, the following step was to process with the Wilcoxon signed-rank test. The Wilcoxon signed-rank test is a statistical comparison of the mean of two dependent samples. The Wilcoxon signed-rank test works with metric data (intervals or proportions) that are not multivariate normal or with sorted or ordered data. The Wilcoxon signed-rank test checks the null hypothesis that the mean of the signed rank of two dependent samples is zero. The Wilcoxon signed-rank test tests the null hypothesis that the mean of the signed rank of two dependent samples is zero.

The first comparison was made with data obtained between the basal and the 5-minute tests while the second comparison was made between the basal and the 7-minute tests. The data were analyzed with IBM® SPSS® Statistics version 26 software using the Wilcoxon signed-rank test for two samples.

The results obtained for the first comparison are shown in Table 3. On the other hand, the results obtained for the second comparison are shown in Table 4.

The Wilcoxon test states that two tests are significantly different if the minimum value of the sum of the ranks is less than the critical value. The critical value of the Wilcoxon signed-rank test for two tests with 15 subjects and an alpha value of 0.05 is set at 25. Therefore, it can be deduced from the results that the 5-minute test has no significant differences with respect to the basal test. On the other hand, the 7-minute test does present significant differences and its use is beneficial to stimulate salivation.

These results are very promising because it establishes that in healthy patients the device starts working after 7 minutes. In this sense, it is important to point out that other chemical treatments need more time and also have undesirable side effects. Probably, in patients whose salivary glands...
are not sufficiently activated due to a certain disease, the duration of treatments with this device should be even longer, but without the side effects typical of chemical treatments.

Therefore, these first tests show an initial good performance of the device, being necessary clinical tests to evaluate its effects on patients.

### 4. Discussion

This study presents the development of a new tool to be validated in patients with salivary hypofunction. In this experiment, we seek to investigate the most effective frequency to increase salivary secretion, without side effects on the skin and orofacial structures.

Physiological conditions such as circadian rhythms, heat, or stress affect salivary flow, which can also be reduced pathologically in various circumstances such as after the use of drugs, head and neck radiotherapy, neurological damage, and metabolic or immunological diseases as the Sjögren’s syndrome [18]. However, the origin, the decrease in unstimulated salivary flow below 0.12-0.16 ml/min and stimulated whole salivary flow rate below 0.5 ml/min causes a dry mouth with significant consequences for the patient.

The use of neuro-electrostimulation as a tool is aimed at stimulating the residual functional parenchyma of the glands and is a new effective proposal for nonpharmacological treatment of oral dryness [19]. Salitron system®, Saliwell GenNarino®, SaliPen®, and Saliwell Crown® (implant-supported miniature device) base their operation on electrical stimulation. These devices have been developed over time, with important modifications, although without great clinical acceptance. The first attempt to exploit neurostimulation to increase salivary secretion was made in the USA, through the design and commercialization of the Salitron device (Biosonics, Fort Washington, PA, USA). The device gave promising results without local adverse effects or system. However, its wider use was hampered by its large size, high price, and lack of ease of use (8). In the studies by [20], we can locate the second generation, which considerably improved the comfort of its use. It is a small intraoral splint, removable, and fully portable by the patient, with two electrodes connected to an electronic module, emerging from a plastic sheet and meeting the lower dental arch of the lingual side to stimulate the lingual nerve. Its use significantly reduces dry mouth not only in direct response to the electrostimulation but also after free intervals without electrostimulation [21]. The other device of this generation is called Salipen®, and it has two arms, which are flexible, with an electrode at the tip of each one, which patients place under their tongue [18]. This device alleviates the feeling of dry mouth over time with no side effects and discomfort. The third generation can be located in the development of a miniature electrical impulse system implanted in the crown of an osteointegrated implant in the mouth, called Saliwell®, which seeks to provide the patient with greater comfort.

| Table 3: The Wilcoxon signed-rank test for basal and 5-minute tests. |
| --- |
| **Ranges** | **N** | **Average rank** | **Sum of ranks** |
| Negative ranges | 4a | 9.63 | 38.50 |
| Positive ranges | 10b | 6.65 | 66.50 |
| **Ties** | 1c |  |  |
| **Total** | 15 |  |  |

(a) 5-minute test < basal. (b) 5-minute test > basal. (c) 5-minute test = basal.

| Table 4: The Wilcoxon signed-rank test for basal and 7-minute tests. |
| --- |
| **Ranges** | **N** | **Average rank** | **Sum of ranks** |
| Negative ranges | 3a | 6.33 | 19.00 |
| Positive ranges | 11b | 7.82 | 86.00 |
| **Ties** | 1c |  |  |
| **Total** | 15 |  |  |

(a) 7-minute test < basal. (b) 7-minute test > basal. (c) 7-minute test = basal.
and provide constant access to the therapy. However, the results of previous trials should be considered with caution, due to poor research methodology, small group study, and, most importantly, short evaluation periods [22].

Another method to stimulate salivary flow is vibratile stimulation. This bases its operation on increasing salivary flow to the area, increasing ultrafiltration (passive transport of compounds from plasma to saliva via the tight junctions between the acinar cells due to a positive hydrostatic pressure). The Japanese guidebook of dental care for elderly people (Koureishya-Shika Guidebook) recommend the vibration of an electric toothbrush as a motor exercise for the increase of blood flow and metabolism in the oral region [23]. In 2007, Yamaoka et al. designed an extraoral device consisting of an oscillating body composed of a headphone headset equipped with vibrators, with an electric motor under each side and an external control unit, connected by a cable which delivered vibration frequencies in the 60–182 Hz range [24]. The device increased the salivary flow of the patients tested, although there are no rigorous works in this regard [16]. We should consider that this type of stimulation could have limitations in patients with early mandibular disorders and/or skin problem.

Xerostomia in the context of neurogenic dysphagia has been anecdotal. However, at present, a guide has been published [25] which they indicate that, in addition to dietary interventions and behavioral treatment of swallowing, interventions to improve oral hygiene, pharmacological treatment, and different neurostimulation modalities are addressed. However, before starting the treatment of dysphagia with a neurostimulation approach where our device can play a role, the pattern of swallowing deficiency should be determined considering that neurostimulation methods should be used as a complement due to the scarcity of data; neurostimulation methods, in principle, should be used only in clinical trials.

The device of vibrotactile stimulation designed by our team comes to alleviate the deficiencies related especially to the comfort of the prototype of Yamaoka et al. being a wireless device, ergonomically designed, and transportable and that has not generated any type of discomfort in the subjects in which it has been tested. We believe that for these reasons, together with the fact that it may not generate rejection of electrical stimulation, it may be a therapeutic tool well accepted by patients with xerostomia.

5. Conclusions
The device shows an acceptable degree of comfort in all the variables analyzed, although the fact that the sample is small must be pointed out as a limitation. It would be necessary to implement a series of changes that would improve the deficiencies in long-term comfort. In addition, preliminary tests show an improvement of salivation in healthy patients when the treatment time is longer than 7 minutes. Therefore, the stimulator shows promising results to start clinical trials with patients. Clinical trials in patients will be set up to confirm the efficacy proven in the tested sample with healthy subjects.

We can conclude that the design of the stimulator seems largely comfortable and functional and it is effective.

Data Availability
Our paper is not based on any external data.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

Authors’ Contributions
All authors have worked in the same way to develop this paper. Professors Díaz-Madrid and Guirao have developed the technical part while Professors López-Jornet, Gómez-García and Guerrero-Sánchez led the medical part.

Acknowledgments
This paper has been partially supported by Fundación Séneca de la Región de Murcia (grant numbers 21084/PDC/19 and 20783/PI/18) and Ministerio de Ciencia, Innovación y Universidades (grant number PGC2018-0971-B-100). The authors want to thank the student Carlos Ernesto Carrazana Concepción who helped us to test our device.

References
[1] R. Matsuo, “Role of saliva in the maintenance of taste sensitivity,” Critical reviews in oral biology & medicine, vol. 11, no. 2, pp. 216–229, 2000.
[2] S. Niklander, L. Veas, C. Barrera, F. Fuentes, G. Chiappini, and M. Marshall, “Risk factors, hyposalivation and impact of xerostomia on oral health-related quality of life,” Brazilian Oral Research, vol. 31, article e14, 2017.
[3] S. B. Jensen, A. M. L. Pedersen, and A. Vissink, “A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact,” Support Care Cancer, vol. 18, pp. 1061–1079, 2010.
[4] A. Villa, A. Wolff, D. Aframian et al., “World workshop on oral medicine VI: a systematic review of medication-induced salivary gland dysfunction: prevalence, diagnosis, and treatment,” Clin Oral Invest, vol. 19, pp. 1563–1580, 2015.
[5] A. Aliko, A. Wolff, C. Dawes et al., “World workshop on oral medicine VI: clinical implications of medication-induced salivary gland dysfunction,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, vol. 120, no. 2, pp. 185–206, 2015.
[6] A. G. Barbe, P. Schmidt, M. Bussmann, H. Kunter, M. J. Noack, and G. Rohrig, “Xerostomia and hyposalivation in orthogeriatric patients with fall history and impact on oral health-related quality of life,” Clinical Interventions in Aging, vol. 13, pp. 1971–1979, 2018.
[7] M. S. Bulthuis, D. H. Jan Jager, and H. S. Brand, “Relationship among perceived stress, xerostomia, and salivary flow rate in patients visiting a saliva clinic,” Clin Oral Invest, vol. 22, pp. 3121–3127, 2018.
[8] D. H. J. Jager, C. P. Bots, and T. Forouzanfar, “Clinical oral dryness score: evaluation of a new screening method for oral dryness,” Odontology, vol. 106, pp. 439–444, 2018.
[9] J. J. Napeñas, M. T. Brennan, and P. C. Fox, “Diagnosis and treatment of xerostomia (dry mouth),” Odontology, vol. 97, pp. 76–83, 2009.
S. Furness, H. V. Worthington, G. Bryan, S. Birchenough, and R. McMillan, “Interventions for the management of dry mouth: non-systemic therapies,” Cochrane Database of Systematic Reviews, vol. 7, 2011.

A. Navarro Morante, A. Wolff, G. R. Bautista Mendoza, and P. López-Jornet, “Natural products for the management of xerostomia: a randomized, double-blinded, placebo-controlled clinical trial,” Journal of Oral Pathology & Medicine, vol. 46, no. 2, pp. 154–160, 2017.

M. P. López-Jornet, G. García-Teresa, M. Viñas, and T. Vinuesa, “Clinical and antimicrobial evaluation of a mouthwash and toothpaste for xerostomia: a randomized, double-blind, crossover study,” Journal of Dentistry, vol. 39, no. 11, pp. 757–763, 2011.

J. A. Gil-Montoya, F. J. Silvestre, R. Barrios, and J. Silvestre-Rangil, “Treatment of xerostomia and hyposalivation in the elderly: a systematic review,” Medicina Oral, Patología Oral y Cirugía Bucal, vol. 1, pp. e355–e366, 2016.

V. Mercadanete, A. Al Hamad, G. Lodi, S. Porter, and S. Fedele, “Interventions for the management of radiotherapy-induced xerostomia and hyposalivation: a systematic review and meta-analysis,” Oral Oncology, vol. 66, pp. 64–74, 2017.

F. P. Strietzel, G. I. Lafaurie, G. R. Mendoza et al., “Efficacy and safety of an intraoral electrostimulation device for xerostomia relief: a multicenter, randomized trial,” Arthritis and Rheumatism, vol. 63, no. 1, pp. 180–190, 2011.

H. Hiraba, M. Yamaoka, M. Fukano, T. Fujiwara, and K. Ueda, “Increased secretion of salivary glands produced by facial vibrotactile stimulation,” Somatosensory and Motor Research, vol. 25, no. 4, pp. 222–229, 2008.

P. López-Jornet, F. Camacho-Alonso, and A. Bermejo-Fenoll, “A simple test for salivary gland hypofunction using Oral Schirmer’s test,” Journal of Oral Pathology & Medicine, vol. 35, no. 4, pp. 244–248, 2006.

N. M. Thie, T. Kato, G. Bader, J. Y. Montplaisir, and G. J. Lavigne, “The significance of saliva during sleep and the relevance of oromotor movements,” Sleep Medicine Reviews, vol. 6, no. 3, pp. 213–227, 2002.

G. Sivaramakrishnan and K. Sridharan, “Electrical nerve stimulation for xerostomia: a meta-analysis of randomised controlled trials,” Journal of Traditional and Complementary Medicine, vol. 7, no. 4, pp. 409–413, 2017.

F. P. Strietzel, R. Martin-Granizo, S. Fedele et al., “Electrostimulating device in the management of xerostomia,” Oral Diseases, vol. 13, no. 2, pp. 206–213, 2007.

A. Wolff, M. Koray, G. Campisi et al., “Electrostimulation of the lingual nerve by an intraoral device may lead to salivary gland regeneration: a case series study,” Oral Medicine and Pathology, vol. 23, no. 5, 2018.

G. Lafaurie, S. Fedele, R. M. López, A. Wolff, F. Strietzel, and S. R. Porter, “Biotechnological advances in neuro-robotic electrostimulation for the treatment of hyposalivation and xerostomia,” Medicina Oral, Patología Oral y Cirugía Bucal, vol. 14, pp. 76–80, 2009.